South Korea's biotechnology company specializing in molecular diagnostics, Seegene Inc. (KQ096530) said Tuesday that it has CE-IVD marked the saliva-based testing application for Allplex™ SARS-CoV-2 Assay and Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay, and that the products with the feature are now available in Europe. The new addition of saliva sample collection feature is set to offload burden of collecting large volume of specimen samples for healthcare professionals on the frontlines of the COVID-19 pandemic. With the newly added feature, the saliva sample collection test can be used interchangeably with nasopharyngeal specimen collection test, normally used for multiplex real-time PCR tests for screening the novel coronavirus. Korea’s leading molecular diagnostics firm said its saliva sample collection test provides additional option for the easy, safe and convenient sample gathering without having to compromise sensitivity and specificity of the test. Separately, a study conducted by Children’s National Hospital in Washington DC taken in the July-to-September period in 2020 showed Seegene’s Allplex™ 2019-nCoV Assay, an earlier version of the company’s COVID-19 diagnostic test, was found to be best suited among the four competing FDA EUA-approved COVID-19 PCR assays for testing saliva specimens collected from participants. It added that the sensitivity of viral detection was equivalent to that of nasopharyngeal specimens when tested on Seegene’s Allplex™ 2019-nCoV Assay. Seegene’s saliva sample collection feature can also eliminate the need for materials and labor associated with nucleic acid extraction, as the test is being performed directly from the raw saliva collected from participants. An official from Seegene said the saliva sample collection feature, together with the extraction-free application, also CE-IVD marked in November, will enable labs to carry out massive testing. The extraction-free application allows labs without extraction equipment, previously a prerequisite for molecular diagnosis testing, and was recently made available in Europe for Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay. Presenting the company’s first ever saliva specimen collection test, an official from Seegene said the new feature is deemed an efficient method of collecting large volume of specimens, especially at a time when mutant coronavirus in Europe has recently prompted global alarm rly December and has exported more than 55 million COVID-19 tests to more than 60 countries in the first three quarters this year. The company recently announced its plans to expand its annual production capacity to KRW 5 trillion by early next year.
Jan 07, 2021View Detail >
Seegene Inc. (KQ096530), a South Korean biotechnology company specializing in molecular diagnostics says it has donated 20,000 COVID-19 tests (Allplex™ SARS-CoV-2 Assay) to Ecuadorian government to help fight the COVID-19 pandemic together. The South Korean company said the COVID-19 tests will be distributed to National Institute for Public Health Research (INSPI) in capital city of Quito and Cuenca as well as to Quito city government. Ecuador's health ministry said as of Tuesday this week, the country has a total of 202,356 confirmed COVID-19 cases with the death toll standing at 9,357. South Korea's leading molecular diagnostic manufacturer said it anticipates the COVID-19 tests will support caregivers in times of need, and added that it also hopes to counter the rapidly spreading virus across South America. It also stressed that in order to curb the spread of coronavirus, the speed of testing should be faster than that of infection. Earlier in November, Ecuador's Foreign Minister Luis Gallegos visited Seegene headquarters in Seoul and expressed gratitude saying that Ecuador is "thankful for Seegene's generosity in donating diagnostic tests." Gallegos added the donations "will become a very meaningful contribution to our government and Ecuadorian people." Seegene had previously contributed COVID-19 tests to government entities and non-profit organizations in the U.S. and to Mexico's health ministry. The company says it plans on supporting communities and governments around the world in the prolonged battle against the COVID-19 pandemic. Seegene's aggregated annual sale surpassed KRW 1 trillion early December and has exported more than 55 million COVID-19 tests to more than 60 countries in the first three quarters this year. The company recently announced its plans to expand its annual production capacity to KRW 5 trillion by early next year.
Dec 17, 2020View Detail >
South Korea’s biotechnology company specializing in molecular diagnosis, Seegene Inc. (KQ096530), announced Monday that its aggregated sales this year have already surpassed the KRW 1 trillion mark, up nearly 10 times its previous annual sales of KRW 120 billion in 2019. This is largely due to an exponential surge in demand for both molecular diagnostic test kits and according PCR instruments, critical in accurately diagnosing patients. Riding on the robust growth in sales, Seegene said it plans on raising its annual production capacity to KRW 5 trillion from the current KRW 2 trillion by the first quarter of 2021. The company’s five production facilities are located in Hanam City, in the vicinity of capital Seoul. Additionally, Seegene recently purchased 10,752 square meters of land in Hanam City, able to handle even greater global demand in the future. With the COVID-19 pandemic, the sales of not only the COVID-19 test kits but the demand for those of other illnesses such as HPV, gastrointestinal infections and sexually transmitted infections also increased significantly. With Seegene’s diverse diagnostic reagent products numbering more than 150, there has been an increasing trend throughout the world to install Seegene’s PCR instruments, which in turn would generate more long-term sales. The company installed more PCR instruments in November alone than it did in the entire year of 2019. As a way to share profit with its shareholders, Seegene also announced that it will boost dividend payouts by a whopping 15 folds to KRW 1,500 for the 2020 fiscal year. The molecular diagnostics firm said it will begin releasing preliminary quarterly earnings disclosure for swift information sharing with the public. An official from Seegene said the ‘COVID-19 pandemic both expanded the molecular diagnostics market and raised Seegene’s brand awareness to the healthcare professionals, government officials and the general public alike.’ He added the ‘demand for molecular diagnostic test to identify coronavirus patients will remain intact even with the introduction of vaccines.’ Learning from the experience of the pandemic, the official added that even ‘in the post COVID-19 era, the molecular diagnostics will be used extensively to properly test and treat patients.’
Dec 14, 2020View Detail >
South Korea's biotechnology company specializing in molecular diagnostics, Seegene Inc. (KQ096530) said Thursday that the extraction-free application of Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay is now available in Europe. Previously in September, Seegene had CE-IVD marked this product with the sales starting in October in Europe. Seegene's Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay is a real-time RT-PCR assay that can simultaneously detect and differentiate 8 target genes including Flu A, Flu B, RSV A/B and three different target genes of COVID-19 (S gene, RdRP gene and N gene), the first and the only test to do so in the world. The Assay also includes dual targets for internal control (endogenous and exogenous respectively) in the same reaction tube, allowing for verification of the whole test process as well as proper sampling without having to compromise the accuracy of test results. Applying extraction-free feature onto Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay is essential in countering the COVID-19 pandemic, recently compounded with influenza and common cold in the winter season. The availability of the extraction-free application allows labs without extraction equipment, previously a prerequisite for molecular diagnosis testing, to test samples for COVID-19 detection in an even shorter turnaround time (TAT). Such technological advancement, not only saves time and cost in testing for the novel Coronavirus, but enables labs to carry out massive testing, whereas before, the testing itself would not have been even possible. An official from Seegene said that it 'hopes the extraction-free application of the assay will help expedite the control of pandemic in Europe.' The company also added that it 'anticipates the addition of the new feature will enable lab researchers to use testing kits more widely throughout the world.' According to Worldometer, the global COVID-19 patients have reached 17,148,406 in November alone, with the U.S. and Europe leading the chart.
Dec 02, 2020View Detail >
Seegene Inc. (KQ096530), a biotechnology company specializing in molecular diagnostics, headquartered in South Korea, reported a record high in sales revenue of KRW 326.9 billion and an operating profit of KRW 209.9 billion for the third quarter in 2020. According to the company, the net profit came in at KRW 152.5 billion, nearly 1000 percent rise from the same period last year. Seegene said the ‘company’s operating profit has increased some 20% on-quarter, on the back of the exponential sales increase in COVID -19-related products in Europe.’ It added that ‘despite large-scale recruitment and investment in production and research in Q3, Seegene reached operating profit to sale ratio of 64% for the quarter and accumulated ratio of 61.2% up to Q3 this year.’ With the record setting quarterly report card, Seegene posted KRW 683.5 billion in consolidated sales, KRW 418.6 billion in operating profit and KRW 317.8 billion in net profit, staying on course to surpass KRW 1 trillion in annual sales. Seegene anticipates that increasing installment of its diagnostics instruments and solutions around the world would further allow the sales growth of COVID-19-related products as well as its other molecular diagnostics products in the post COVID-19 era. The company said it has ‘introduced another diagnostic kit in Europe that can detect multiple respiratory diseases with a single tube,’ and forecasts the business profit rate to surpass 60% and annual sales revenue to reach KRW 1 trillion for the year. Through addition of production and research facilities and pursuance of large-scale recruitment, Seegene aims to continue its steady growth in 2021.
Nov 12, 2020View Detail >
Apr 10, 2020View Detail >